Shanghai Chest Hospital

Phase 3 POD1UM-304 trial of retifanlimab met primary endpoint of overall survival (OS) and all secondary endpoints in previously untreated metastatic non-small cell lung cancer (NSCLC). Median OS was 18.1 months in the retifanlimab and chemotherapy group vs. 13.4 months in the placebo group. Data support planned 2025 filing of a supplemental Biologics License Application (sBLA) in the U.S.

POD1UM-304 trial results show retifanlimab + chemotherapy significantly improves median overall survival in NSCLC patients to 18.1 months vs. 13.4 months with placebo + chemotherapy (HR: 0.75; P=0.0042). Retifanlimab was well-tolerated, with no new safety issues identified.

Shanghai Chest Hospital to start a CAR-T cell therapy clinical trial for lung cancer in January, involving 20 patients. China's lung cancer treatment capabilities are nearly on par with developed countries, with rapid access to advanced treatments. Molecular typing technology enables precise treatment, and China's innovative medicines are close to those in the US. International collaboration and exchange are emphasized for continuous advancement.

Ku70, known for DNA repair, promotes Treg suppressive function via FOXP3-dependent mechanism in lung adenocarcinoma, suggesting Ku70 targeting as a cancer therapy strategy.